St. Jude Medical (NYSE:STJ) said Monday that a study of its Axium dorsal root ganglion neurostimulator showed superior pain relief compared to traditional spinal cord stimulation in treating chronic lower limb pain associated with complex regional pain syndrome.
The the 152-patient Accurate study reported that 81.2% of patients treated with the Axium system achieved significant pain relief, compared to 55.7% treated with traditional SCS, St. Paul, Minn.-based St. Jude said. Patients also reported less posture-based paresthesia intensity with DRG, and were less likely to report stimulation outside the area of pain, the company added.
“Data from the Accurate study are exciting because they demonstrate that DRG stimulation can offer meaningful improvement over traditional spinal cord stimulation for patients suffering from chronic pain conditions that have historically been challenging to treat. We look forward to continuing to develop DRG stimulation therapy to expand availability for patients currently underserved by traditional chronic pain therapy options,” CMO Dr. Mark Carlson said in a press release.
The study will go to support FDA approval of DRG stimulation, the company said. The Axium system received CE Mark approval in the European Union in November 2011 for indications of chronic, intractable pain.
Earlier this month, St. Jude said it won CE Mark approval in the European Union for its Inivisible Trial app-based wireless SCS neuromodulation system.